Purpose of review
The assessment of pretest probability, allowing the categorization of patients clinically suspected of having pulmonary embolism
in low, intermediate, and high clinical probability
, is an essential step in contemporary diagnostic strategies because it permits limiting the number of additional diagnostic tests, especially invasive tests. Clinical probability
can be evaluated implicitly or by prediction rules. Two prediction rules for pulmonary embolism
have been described: the Canadian prediction rule (the Wells score) and the Geneva prediction rule. Their original descriptions were published in 2000 and 2001, respectively. These prediction rules need to be externally validated, and, ideally, outcome studies should demonstrate that patients may be safely treated on the basis of the assessment of the clinical probability
they provide. Therefore, the purpose of this review is to discuss the external validation of these rules, because this particular point has been only recently achieved.
Application of both rules in an external setting and in a prospective study have confirmed their validity. A recent study suggests that the best evaluation is probably based on a prediction rule associated with possible clinical override.
Studies comparing an empiric assessment with explicit assessment, such as the Wells simplified score or the Geneva score, have shown that the three tools show similar accuracy. External validation and use of both rules in prospective management studies have only recently been performed and have confirmed their validity. Some reports suggest that empiric assessment may be influenced by level of training. Objective prediction rules seems to be less influenced by experience and should be preferred by more junior doctors. The tool used for clinical probability
assessment is probably less important than the principle of a careful clinical probability
assessment in each patient with suspected pulmonary embolism